Author: healthadmin
Older people who begin to feel lonely experience an accelerated decline in cognitive function compared to their peers. A new analysis of long-term health records shows that memory and thinking skills decline at a similar rate until people first experience loneliness, at which point the trajectory of cognitive decline accelerates. The study was published in the Journal of Affective Disorders. As the global population ages, finding ways to protect memory and maintain individual independence has become a major public health priority. Medical professionals are always looking for risk factors that can be improved through lifestyle changes or treatment. Beyond physical…
Four years after winning FDA approval for Overity to treat major depressive disorder (MDD), Axum Therapeutics has launched its second U.S. approval for a first-in-class drug to treat agitation associated with dementia caused by Alzheimer’s disease. The new approval (PDF) will keep Auvelity in competition with Lundbeck and Otsuka Pharmaceutical’s atypical antipsychotic Rexulti. Rexulti has been on the market for 10 years as a treatment for schizophrenia and MDD, and is on track to be approved for irritability in Alzheimer’s disease in 2023. Both are oral medications, making Auvelity the first non-antipsychotic drug option for new indications. Another point of…
Shortly after paying $75 million up front for Corstasis Therapeutics and its congestive heart failure edema treatment Enbumyst, Esperion Therapeutics itself was acquired by healthcare investment firm Archimed and taken private. On Friday, the companies announced that Archimed will pay $3.16 per share for Esperion at the close of trading on May 1. In addition, CVR mitigation could include contingent milestone payments tied to future sales performance for Esperion’s Nexletol, Nexlizet and Enbumyst, which could reach up to $100 million. Overall, the deal could be worth up to $1.1 billion, assuming these commercial milestones are achieved, the companies said in…
Researchers at the University of Oxford have demonstrated a new type of quantum interaction using a single trapped ion. By carefully generating and controlling increasingly complex forms of ‘squeezing’, including a fourth-order effect called quad-squeezing, we are now able to harness quantum behavior that was previously out of reach. This research also introduces new ways to engineer these interactions, with potential applications in quantum simulation, sensing, and computing. The results of this survey were announced today (May 1st). natural physics. Many physical systems behave like small vibrating objects, similar to springs or pendulums. In quantum physics, these are known as…
A recent study assessing sexual well-being in the United States suggests that while many people report positive and desired sexual experiences, significant gaps remain in testing, communication, and overall satisfaction. Published in Sex & Couple Therapy Journalthe findings show evidence of persistent gender disparities and widespread lack of access to preventive care. These insights highlight the need for a more comprehensive approach to reproductive and sexual well-being across the country. Public health efforts in the United States have traditionally approached sexual health through narrow categories. Government and state programs tend to focus on preventing specific diseases and managing family planning.…
A team of scientists from King’s College London has identified a new form of aluminum, one of the most abundant metals on Earth, that could provide a much cheaper and more sustainable alternative to widely used rare earth metals. Under the guidance of Dr Claire Bakewell, a senior lecturer in the Department of Chemistry, the researchers created highly reactive aluminum molecules that can break some of the strongest chemical bonds. Their findings were; nature communicationsentirely new molecular structures are also revealed, opening the door to previously unknown types of chemical behavior. Discovering a unique aluminum structure Researchers have reported the…
Get the health information and medications you need every weekday with STAT’s free newsletter Morning Rounds. Sign up here. There was so much news yesterday, so I’m linking to the latest article about the FDA selecting Vinay Prasad’s interim successor. President Trump withdraws Casey Means’ general nomination as surgeon general The White House withdrew its nomination of Casey Means to be the next Surgeon General and replaced her with radiologist and Fox News contributor Nicole Safier. The exchange shows the limits of the Trump administration’s power in the Senate and is a blow to the months-long “Make America Healthy Again”…
This is a pivotal year for Ionis Pharmaceuticals, a pioneer in RNA therapeutics. After moving from a partnership model to a wholly owned strategy following Tringorza’s 2024 approval, the company is counting on the FDA’s decision to expand the drug into severe hypertriglyceridemia as its first non-orphan indication for a wholly owned product. Meanwhile, potentially game-changing Phase 3 results are expected from Ionis’ lipoprotein(a) candidate in partnership with Novartis and the ATTR cardiomyopathy program in partnership with AstraZeneca. On this week’s episode of The Topline, Fierce’s Angus Lew interviews Dr. Brett Monier, CEO of Ionis. He talks about the science…
Sun Pharma will acquire Organon for $11.75 billion. Astellas Pharma predicts that sales of Xtandy will decline in fiscal 2026. B-One Medicines is entering the PD-1xVEGF race with a trispecific antibody option. moreover. 1. Sun Pharma acquires Organon for $11.75 billion, sealing the biopharmaceutical industry’s largest deal in 26 years Sun Pharma inked a deal to buy Organon for $11.75 billion in the biggest biopharmaceutical acquisition so far this year and the largest ever by an Indian drug company. The partnership will make Sun the seventh largest seller of biosimilars. And Organon’s skin cream Vtama fits into Sun’s specialty dermatology…
The pharmaceutical sector faces patent cliffs and rising costs. Explore 2026 trends in AI drug discovery, gene therapy, biopharma manufacturing, clinical pipelines, and FDA approvals to drive efficiency and innovation.